Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:HRTX NASDAQ:MNPR NASDAQ:MREO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.44-2.1%$0.39$0.30▼$10.62$63.71M1.961.57 million shs673,519 shsHRTXHeron Therapeutics$1.69-2.3%$2.01$1.04▼$2.88$263.94M1.18911,753 shs1.02 million shsMNPRMonopar Therapeutics$40.69-1.2%$37.43$1.72▼$54.30$251.82M1.0534,661 shs35,807 shsMREOMereo BioPharma Group$1.66-1.8%$2.35$1.57▼$5.02$268.71M0.474.47 million shs1.03 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-2.07%-8.19%+30.27%-4.28%-92.58%HRTXHeron Therapeutics-2.31%-11.52%-21.40%-26.84%-43.10%MNPRMonopar Therapeutics-1.19%-9.52%+15.73%-9.50%+1,095.01%MREOMereo BioPharma Group-1.78%-5.68%-42.16%-37.83%-59.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.1789 of 5 stars3.33.00.04.71.91.71.3HRTXHeron Therapeutics3.7234 of 5 stars3.51.00.04.22.01.70.6MNPRMonopar Therapeutics1.9601 of 5 stars3.43.00.00.00.62.50.0MREOMereo BioPharma Group1.3591 of 5 stars3.61.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,284.16% UpsideHRTXHeron Therapeutics 3.00Buy$5.00195.86% UpsideMNPRMonopar Therapeutics 2.83Moderate Buy$60.0047.46% UpsideMREOMereo BioPharma Group 3.20Buy$7.20333.73% UpsideCurrent Analyst Ratings BreakdownLatest APLT, HRTX, MNPR, and MREO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$7.00 ➝ $5.007/7/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.006/23/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.006/9/2025HRTXHeron TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/14/2025APLTApplied TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.505/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$460K135.64N/AN/A$0.49 per share0.90HRTXHeron Therapeutics$148.52M1.74N/AN/A($0.22) per share-7.68MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/AMREOMereo BioPharma Group$10M26.39N/AN/A$0.39 per share4.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/11/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)Latest APLT, HRTX, MNPR, and MREO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MREOMereo BioPharma Group-$0.01N/AN/AN/AN/AN/A8/11/2025Q2 2025HRTXHeron Therapeutics-$0.01N/AN/AN/A$38.08 millionN/A8/8/2025N/AMNPRMonopar Therapeutics-$0.47N/AN/AN/AN/AN/A8/6/2025Q2 2025APLTApplied Therapeutics-$0.17N/AN/AN/A$0.42 millionN/A5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A3.003.00HRTXHeron TherapeuticsN/A2.401.76MNPRMonopar TherapeuticsN/A36.9136.91MREOMereo BioPharma GroupN/A8.928.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%HRTXHeron Therapeutics80.01%MNPRMonopar Therapeutics1.83%MREOMereo BioPharma Group62.83%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%HRTXHeron Therapeutics5.86%MNPRMonopar Therapeutics20.50%MREOMereo BioPharma Group5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30141.58 million139.31 millionOptionableHRTXHeron Therapeutics300152.56 million143.62 millionOptionableMNPRMonopar Therapeutics106.12 million4.86 millionNot OptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableAPLT, HRTX, MNPR, and MREO HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOJuly 31 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOJuly 28, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOJuly 27, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOJuly 22, 2025 | prnewswire.comMereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Consensus Rating of "Buy" by BrokeragesJuly 19, 2025 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Lowered to Sell Rating by Wall Street ZenJuly 19, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOJuly 17, 2025 | prnewswire.comMereo BioPharma Group Stock Short Interest Report | NASDAQ:MREO - BenzingaJuly 11, 2025 | benzinga.comMereo BioPharma Group Analyst Ratings and Price Targets | NASDAQ:MREO ...July 11, 2025 | benzinga.comMereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OIJuly 10, 2025 | seekingalpha.comRARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year EndJuly 10, 2025 | zacks.comUltragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall ShortJuly 10, 2025 | biospace.comBUltragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone DiseaseJuly 10, 2025 | investors.comMereo BioPharma Group (NASDAQ:MREO) Price Target Lowered to $5.00 at Needham & Company LLCJuly 10, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc.: Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final AnalysisJuly 10, 2025 | finanznachrichten.deMereo BioPharma Group plc (MREO) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comUltragenyx, Mereo Slide as Drug Study Progresses to Final AnalysisJuly 9, 2025 | marketwatch.comMREO | Mereo BioPharma Group PLC ADR - Wall Street JournalJune 29, 2025 | wsj.comMereo rebrands as Cedar TraceJune 10, 2025 | royalgazette.comRWhy Mereo BioPharma Group plc’s (MREO) Stock Is Down 5.63%May 16, 2025 | aaii.comAWe're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn RateMay 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPLT, HRTX, MNPR, and MREO Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.44 -0.01 (-2.07%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.52%) As of 08/1/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Heron Therapeutics NASDAQ:HRTX$1.69 -0.04 (-2.31%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.83%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Monopar Therapeutics NASDAQ:MNPR$40.69 -0.49 (-1.19%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$40.56 -0.13 (-0.31%) As of 08/1/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Mereo BioPharma Group NASDAQ:MREO$1.66 -0.03 (-1.78%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.67 +0.01 (+0.66%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
